Status:
COMPLETED
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Lymphoma, Non-Hodgkin
Blood and Marrow Transplant (BMT)
Eligibility:
All Genders
18-61 years
Phase:
PHASE2
Brief Summary
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Detailed Description
To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical ...
Eligibility Criteria
Inclusion
- Morphologically confirmed relapsed non-Hodgkin's lymphoma
- Age: \>18 and \<61 years of age
- Signed informed consent
Exclusion
- Hepatic dysfunction defined by serum transaminases \>2.5X normal values
- Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min
- Diseases other than non-Hodgkin's lymphoma
- Prior bone marrow transplant procedure
- Severe psychological or medical illness
Key Trial Info
Start Date :
April 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00186394
Start Date
April 1 2000
End Date
December 1 2006
Last Update
July 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305